In Nashville, Tennessee, nurses and doctors hoped to motivate others by rolling up their sleeves first. There s a lot of misinformation going on and people are just scared, said Salomey Agyemang, a registered nurse at Southern Hills Medical Center. I want to be one of the first people to do it so I can pass on that comfort to someone else so that they will also be encouraged to go for it.
Tennessee has one of the highest daily case averages in the United States, so the vaccine could not have come at a more dire time. This is a historic moment for all of us, said Prakash Patel, chief medical officer at Nashville s TriStar StoneCrest Medical Center. I believe it s the beginning of the end of the pandemic. We ve been struggling since March and this will make a big difference.
What it s like to get the COVID-19 vaccine, according to some of the first healthcare workers to receive it Samara Abramson, Shelby Livingston, Amelia Kosciulek Healthcare workers in Nashville, Tennessee, were some of the first to receive Pfizer s COVID-19 vaccine. The workers hope that getting the vaccine will motivate others to get it when it becomes more widely available. Nashville has one of the highest COVID-19 case rates in the country.
In Nashville, Tennessee, nurses and doctors hoped to motivate others by rolling up their sleeves first. There s a lot of misinformation going on and people are just scared, said Salomey Agyemang, a registered nurse at Southern Hills Medical Centre. I want to be one of the first people to do it so I can pass on that comfort to someone else so that they will also be encouraged to go for it.
CRISPR Gene Editing Delivers Promise for Sickle-Cell Disease, Beta Thalassemia
CRISPR Therapeutics CEO Samarth Kulkarni, PhD
CRISPR Therapeutics and Vertex Pharmaceuticals have reported a consistent and sustained positive response in 10 patients treated for a pair of blood disorders sickle-cell disease (SCD) and beta thalassemia with their CRISPR-Cas9 gene-edited therapy CTX001 in a pair of Phase I/II trials. These are the first clinical studies of a CRISPR gene-editing candidate sponsored by U.S. companies.
According to data published last Saturday in the
New England Journal of Medicine (NEJM) and presented Sunday at the annual American Society of Hematology (ASH) Meeting and Exposition, all seven patients with transfusion-dependent beta thalassemia (TDT) including three who have either a severe or b0/b0 genotype were transfusion independent at the last follow-up in the TDT trial, which is known as CLIMB-111 (NCT03655678).